John S. Markowitz, Pharm.D., BCPP

John S. Markowitz

Professor

Pharmacotherapy and Translational Research

OFFICE: HSC PG-23

EMAIL: jmarkowitz@cop.ufl.edu

PHONE: (352) 273-6262

CV: Link to CV

 

Education

  • ASHP accredited residency in Psychiatric Pharmacy University of Tennessee College of Pharmacy, Memphis, Tennessee
  • Pharm.D., University of Tennessee College of Pharmacy
  • B.S. in Biology, with a concentration in microbiology, Memphis State University

Biographical Sketch

Following his training, Dr. Markowitz served for a decade as a Clinical Specialist in Psychiatry, and eventually Clinical Coordinator within the Institute of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He eventually entered into a primary faculty research position in the MUSC College of Pharmacy’s Department of Pharmaceutical & Biomedical Sciences with a dual appointment in the Department of Psychiatry and Behavioral Sciences where he had remained prior to joining the UF College of Pharmacy in 2009. Dr. Markowitz has been credentialed by the Board of Pharmaceutical Specialties in Psychiatric Pharmacy (BCPP) since 1997 and is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP)

Affiliations

  • American Society of Hospital Pharmacists
  • American Society of Clinical Pharmacology and Therapeutics
  • American College of Clinical Pharmacy
  • College of Psychiatric and Neurologic Pharmacists

Research Interests

Dr. Markowitz’s research program has encompassed both in vitro and in vivo investigations including normal volunteer pharmacokinetic studies directed at the assessment of drug-drug interactions in psychiatric pharmacy, botanical-drug interactions, as well as their associated clinical effects. More recently, the research program has focused on variability in drug metabolism, disposition, and therapeutic response as a consequence of genetic variability influencing both drug transporters and hepatic enzymes. The serine esterase carboxylesterase 1 (CES1) is of particular interest. Dr. Markowitz has received research support from both the pharmaceutical industry and the National Institutes of Health (NIH) serving as the principal investigator of research grants funded by an array of institutes including NCCAM, NIDA, NIAID, and NICHD

Research Group Members

  • Yuli Qian, MS – Graduate student
  • Tara Gilliland – Pharm.D. student
Yuli Lab

Yuli Qian

Recent Grants

1 R01 HD093612-01A1: “Carboxylesterase 1 genetic variation and methylphenidate in ADHD” NIH National Institute of Child Health and Human Development (NICHD), Principal Investigator, (07/01/2018-6/30/2023)

Recent Publications

Qian Y, Wang X, Markowitz JS. In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos 2019; 47:465-472 (PMID 30833288)

Steingard R, Taskiran S, Connor D, Markowitz JS, Stein MA. New formulations of stimulants: An update for clinicians. J Child Adolesc Psychopharmacol 2019;29:1-16. DOI: 10.1089/cap.2019.0043 (PMID: 31038360)

Gurley BJ, Yates CR, Markowitz JS. “…Not intended to diagnose, treat, cure or prevent any disease.” 25 years of botanical dietary supplement research and the lessons learned. Clin Pharmacol Ther 2018;104:470-483 (PMID 29882958)

Markowitz JS, Patrick KS. The clinical pharmacokinetics of amphetamines utilized in the treatment of ADHD. J Child Adolesc Psychopharmacol 2017;8:678-689 (PMID 28910145)

Zhu HJ, Patrick KS, Straughn AB, Reeves OT, Bernstein H, Shi, H, Johnson HJ, Knight, JM, Smith AT, Malcolm RJ, Markowitz JS. Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers. J Clin Psychopharmacol 2017;37:419-428 (PMID 28590363)

Full Publication List via PubMed RSS feed